If we can measure brain health better, we can develop better treatments.

For years, the pharmaceutical industry has struggled to develop new treatments for brain disorders. Not because of a lack of ideas, but because researchers haven’t been able to see what’s really happening in the brain often enough.

Traditional clinic visits provide only snapshots — not the continuous, real-world insights needed to understand whether a disease is progressing or a drug is working.

This problem was brought into sharp focus at the Dementia Discovery Fund’s (DDF) Annual Forum, where leaders from pharma highlighted a clear need: Frequent, reliable, at-home measures of brain function, including EEG.

A Shared Vision Takes Shape

To explore what an ideal solution might look like, DDF gathered scientists from major pharmaceutical companies. After a year of collaboration, they identified six key requirements for a platform that could meaningfully support CNS trials.

Around this time, BrainWaveBank Ltd. was already building technology that aligned with this vision — an easy-to-use at-home EEG headset, synchronized cognitive assessments on a tablet, and AI-powered analytics to interpret the data.

Bringing It All Together

With funding from DDF and LifeArc, these innovations were combined in 2020 to create Cumulus Neuroscience — who set out to build NeuLogiq, a single, unified platform designed to meet all six requirements set by the pharma panel.

To ensure the technology met real industry needs, feasibility studies were carried out with scientists from ten global pharma companies, now known as the Cumulus Pharma Advisory Group (CPAG).